SCHEMBL2616807

SCHEMBL2616807

Cc1ncc(-c2ccc3ccccc3c2)cn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 3/20 0.52
CYP11B2 P19099 3/20 0.52
CYP17A1 P05093 1/20 0.52
CYP19A1 P11511 1/20 0.52
ESR1 P03372 1/20 0.48
ESR2 Q92731 1/20 0.48
ALOX5 P09917 1/20 0.47
CYP1A2 P05177 3/20 0.46
ALDH1A1 P00352 2/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HSD17B10 Q99714 1/20 0.46
DHFR P00374 1/20 0.46
HSD17B1 P14061 1/20 0.46
HSD17B2 P37059 1/20 0.46
CYP2A6 P11509 2/20 0.45
TDP1 Q9NUW8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15977432 0.86 IKBKB (0.41) CYP11B1CYP11B2CYP17A1CYP19A1ESR1
SCHEMBL15977524 0.84 IKBKB (0.40) CYP11B1CYP11B2CYP17A1CYP19A1ESR1
SCHEMBL890113 0.84 CYP1A2 (0.52) CYP1A2ALDH1A1CYP3A4CYP2C9HPGD
SCHEMBL12359230 0.82 CYP11B2 (0.59) CYP11B1CYP11B2CYP17A1CYP19A1ESR1
SCHEMBL10147747 0.82 FTO (0.41) CYP11B1CYP11B2CYP17A1CYP19A1ALDH1A1
SCHEMBL25763711 0.81 CYP11B1 (0.49) CYP11B1CYP11B2CYP17A1CYP19A1ESR1
SCHEMBL3648882 0.80 CYP11B1 (0.52) CYP11B1CYP11B2CYP17A1CYP19A1ESR1
SCHEMBL27785002 0.79 CYP11B1 (0.47) CYP11B1CYP11B2CYP17A1CYP19A1ESR1
SCHEMBL15977556 0.79 PSMB5 (0.40) CYP11B1CYP11B2CYP17A1CYP19A1ESR1
SCHEMBL17899315 0.78 CYP11B1 (0.53) CYP11B1CYP11B2CYP17A1CYP19A1ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230363260-A1 ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2023-11-09 US disclosed
US-11730053-B2 Organic light-emitting device SAMSUNG DISPLAY CO., LTD. (KR) 2023-08-15 US disclosed
US-11217758-B2 Organic light-emitting device SAMSUNG DISPLAY CO., LTD. (KR) 2022-01-04 US disclosed
US-10826000-B2 Organic light-emitting device SAMSUNG DISPLAY CO., LTD. (KR) 2020-11-03 US disclosed
US-20200321538-A1 ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2020-10-08 US disclosed
US-10727418-B2 Organic light-emitting device SAMSUNG DISPLAY CO., LTD. (KR) 2020-07-28 US disclosed
US-10305041-B2 Organic light-emitting device SAMSUNG DISPLAY CO., LTD. (KR) 2019-05-28 US disclosed
US-20190036043-A1 ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2019-01-31 US disclosed
US-10026906-B2 Condensed cyclic compound and organic light-emitting device including the same SAMSUNG DISPLAY CO., LTD. (KR) 2018-07-17 US disclosed
US-9972789-B2 Organic light-emitting device SAMSUNG DISPLAY CO., LTD. (KR) 2018-05-15 US disclosed
US-9887364-B2 Organic light-emitting devices SAMSUNG DISPLAY CO., LTD. (KR) 2018-02-06 US disclosed
US-9818950-B2 Organic light-emitting devices SAMSUNG DISPLAY CO., LTD. (KR) 2017-11-14 US disclosed
US-9666807-B2 Organic light emitting device SAMSUNG DISPLAY CO., LTD. (KR) 2017-05-30 US disclosed
US-20160111664-A1 ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2016-04-21 US disclosed
US-20160111664-A1 ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2016-04-21 US disclosed
US-20160028017-A1 ORGANIC LIGHT EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2016-01-28 US disclosed
US-20150171337-A1 AMINE-BASED COMPOUNDS AND ORGANIC LIGHT-EMITTING DEVICES COMPRISING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2015-06-18 US disclosed
US-8163756-B2 For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, LLC (US) 2012-04-24 US disclosed
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2008-05-15 US disclosed
US-20070078121-A1 Enzyme modulators and treatments DECIPHERA PHARMACEUTICALS, LLC 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10026906-B2 Condensed cyclic compound and organic light-emitting device including the same CRY1, CCNL2, CRY2 CYP11B1 758/4885CYP11B2 751/4885CYP17A1 1063/4885
US-20070078121-A1 Enzyme modulators and treatments ABL1, ABL2, LCK CYP11B1 2941/4885CYP11B2 3164/4885CYP17A1 2241/4885
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS ABL2, BRAF, MAP3K1 CYP11B1 2934/4885CYP11B2 3086/4885CYP17A1 2918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.